Skip to main content
SpringerLink
Log in

CAP-B maintenance not cost effective for metastatic CRC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Franken MD, et al. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer. European Journal of Cancer 75: 204-212, 23 Feb 2017. Available from: URL: http://doi.org/10.1016/j.ejca.2017.01.019

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

CAP-B maintenance not cost effective for metastatic CRC. PharmacoEcon Outcomes News 773, 12 (2017). https://doi.org/10.1007/s40274-017-3797-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3797-y

Search

Navigation